Patients with a family history of cancer: Identification and management

Journal of the American Board of Family Practice

Volumn 18, Issue 3, 2005, Pages 211-217

  Eberl, Margaret M ^a,b,c   Sunga, Annette Y ^a,b,c   Farrell, Carolyn D ^a   Mahoney, Martin C ^a,b,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CARCINOGENESIS; COUNSELING; FAMILY HISTORY; GENE MUTATION; HUMAN; LIFESTYLE; OVARY CANCER; PROSTATE CANCER; REVIEW; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; MASS SCREENING; METHODOLOGY; NEOPLASM; RISK ASSESSMENT; RISK FACTOR;

EPIDEMIOLOGIC STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASS SCREENING; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 23044504937     PISSN: 08938652     EISSN: 15448770     Source Type: Journal    
DOI: 10.3122/jabfm.18.3.211     Document Type: Review

References (41)

1. Offit K, Brown K. Quantitating familial cancer risk: a resource for clinical oncologists. J Clin Oncol 1994;12:1724-36.
2. Chew HK. Genetic evaluation of cancer: the importance of family history. Tex Med 2001;97:40-5.
3. Sifri R, Gangadharappa S, Acheson LS. Identifying and testing for hereditary susceptibility to common cancers. CA Cancer J Clin 2004;54:309-26.
4. Weitzel JN. Genetic cancer risk assessment. Putting it all together. Cancer 1999;86(11 Suppl):2483-92.
5. Murff HJ, Byrne D, Syngal S. Cancer risk assessment: quality and impact of the family history interview. Am J Prev Med 2004;27:239-45.
6. Ang P, Garber JE. Genetic susceptibility for breast cancer: risk assessment and counseling. Semin Oncol 2001;28:419-33.
7. Sifri RD, Wender R, Paynter N. Cancer risk assessment from family history: gaps in primary care practice. J Fam Pract 2002;51:856.
8. Daly M, Farmer J, Harrop-Stein C, et al. Exploring family relationships in cancer risk counseling using the genogram. Cancer Epidemiol Biomarkers Prev 1999;8:393-8.
9. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 1996;14:1730-6; discussion 1737-40.
10. National Comprehensive Cancer Network. Clinical practice guidelines in oncology [monograph on the Internet]. Jenkintown (PA): National Comprehensive Cancer Network; 2005 [cited 2005 Jan 18]. Available from: http://www.nccn.org/ professionals/physician_gls/default.asp.
11. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997;71:800-9.
12. Colditz GA, Willett WC, Hunter DJ, et al. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA 1993;270:338-43.
13. Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA 1993;270:1563-8.
14. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
15. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
16. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-24.
17. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457-62.
18. Emery J, Lucassen A, Murphy M. Common hereditary cancers and implications for primary care. Lancet 2001;358:56-63.
19. Myriad Genetics [homepage on the Internet]. Salt Lake City (UT): Myriad Genetics [cited 2005 Feb 7]. Available from: http://www.myriad.com/index.htm.
20. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
21. Lynch HT, Snyder CL, Lynch JF, Riley BD, Rubinstein WS. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J Clin Oncol 2003;21:740-53.
22. Evans DG, Lalloo F. Risk assessment and management of high risk familial breast cancer. J Med Genet 2002;39:865-71.
23. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003;53:141-69.
24. Daly M, Bryant E, Buys S, Ellis, CL. NCCN Practice Guidelines: genetic/familial high-risk assessment: breast and ovarian [monograph on the Internet]. Jenkintown (PA): National Comprehensive Cancer Network; 2004 [cited 2005 Jan 18]. Available from: http://www.nccn.org/professionals/physician_ gls/PDF/genetics_screening.pdf.
25. Lewis S, Menon U. Screening for ovarian cancer. Expert Rev Anticancer Ther 2003;3:55-62.
26. Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA 1995;273:577-85.
27. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994;331:1669-74.
28. Ivanovich JL, Read TE, Ciske DJ, Kodner IJ, Whelan AJ. A practical approach to familial and hereditary colorectal cancer. Am J Med 1999;107:68-77.
29. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001-testing for early lung cancer detection. CA Cancer J Clin 2001;51:38-75; quiz 77-80.
30. Burt RW. Familial risk and colon cancer. Int J Cancer 1996;69:44-6.
31. Levin B, Barthel J, David D, et al. Clinical practice guidelines in oncology, colorectal screening, version 1 [monograph on the Internet]. Jenkintown (PA): National Comprehensive Cancer Network; 2005 [cited 2005 Jan 18]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/ colorectal_screening.pdf.
32. Lynch HT, Smyrk T, Lynch JF. Overview of natural history, pathology, molecular genetics and manage ment of HNPCC (Lynch syndrome). Int J Cancer 1996;69:38-43.
33. Lynch HT, Smyrk T, Lynch J. An update of HNPCC (Lynch syndrome). Cancer Genet Cyto-genet 1997;93:84-99.
34. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-10.
35. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on HNPCC. Dis Colon Rectum 1991;34:424-5.
36. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-6.
37. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990;17:337-47.
38. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
39. Scardino P, Bahnson R, Hanks G, Trump D, et al. Clinical practice guidelines in oncology. Prostate cancer. Version 1 [monograph on the Internet] Jenkin-town (PA): National Comprehensive Cancer Network; 2003 [cited 2005 Jan 18]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/ prostate.pdf.
40. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Huntingt) 2000;14:267-72, 277-8, 280 passim.
41. American Urological Association [homepage on the Internet]. Linthicum (MD): American Urological Association; c2005 [cited 2005 Jan 18]. Available from: http://www.urologyhealth.org/index.cfm.